Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Buprenorphine-naloxone treatment for opioid use disorder has rapidly expanded, yet little is known about treatment outcomes among patients in the general population. Objective: To examine predictors of treatment duration, dosage, and continuity in a diverse community setting. Research Design: We examined QuintilesIMS Real World Data, an all-payer, pharmacy claims database, to conduct an analysis of individuals age 18 years and above initiating buprenorphine-naloxone treatment between January 2010 and July 2012 in 11 states. We used logistic regression to assess treatment duration longer than 6 months. We used accelerated failure time models to assess risk of treatment discontinuation. We used ordinary least squares regression to assess mean daily dosage. For patients with ≥3 fills, we also used logistic regression to assess whether ;an individual had a medication possession ratio of <80% and/or gaps in treatment >14 days. Models adjusted for individual demographics, prescribing physician specialty, state, and county-level variables. Results: Overall, 41% of individuals were retained in treatment for at least 6 months and the mean treatment length was 266 days. Compared with individuals who paid primarily for treatment with cash, adjusted odds of 6 month retention were significantly lower for individuals with primary payment from Medicaid fee-for-service, Medicare part D, and third-party commercial. There were substantial differences in 6-month retention across states with the lowest in Arizona and highest in New York. Low-possession ratios occurred for 30% of individuals and 26% experienced treatment episodes with gaps >14 days. Odds of low-possession and treatment gaps were largely similar across demographic groups and geographic areas. Conclusions: Current initiatives to improve access and quality of buprenorphine-naloxone treatment should examine geographic barriers as well as the potential role of insurance benefit design in restricting treatment length.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · cited 1×
“Many patients value the convenience of receiving treatment on a prescription basis as compared with methadone maintenance, which typically is more managed than buprenorphine maintenance.(3) Patients generally experience better long-term outcomes when retained in treatment for longer periods of time and with greater co…”
BackgroundFudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.541 · Cited by 267
Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007) · The Annals of Family Medicine · doi:10.1370/afm.665 · Cited by 117
Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program
Gordon, A. J., Lo-Ciganic, W.-H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000164 · Cited by 76
Cited by
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
Samples, H., Williams, A. R., Olfson, M., & Crystal, S. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.09.001 · Cited by 235
Krawczyk, N., Mojtabai, R., Stuart, E. A., Fingerhood, M., Agus, D., Lyons, B. C., Weiner, J. P., & Saloner, B. (2020) · Addiction · doi:10.1111/add.14991 · Cited by 177
Self-citationBarocas, J. A., Morgan, J. R., Wang, J., McLoone, D., Wurcel, A., & Stein, M. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa062 · Cited by 48
Metadata
- Authors
- Saloner, B., Daubresse, M., & Caleb Alexander, G.
- Venue
- Medical Care
- Published
- 2017-07
- Volume
- 55
- Issue
- 7
- Pages
- 669-676
- ISSN
- 0025-7079 (ISSN-L)
- OpenAlex
- W2605608745
- Cited by
- 87
- References
- 5
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population. https://app.cochat.ai/papers/10.1097/mlr.0000000000000727
- The paper
- Saloner, B., Daubresse, M., & Caleb Alexander, G. (2017). Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population. Medical Care. https://doi.org/10.1097/mlr.0000000000000727
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.